Impact of frequency of COPD exacerbations on pulmonary function, health status and clinical outcomes

A Anzueto, I Leimer, S Kesten, A Anzueto, I Leimer, S Kesten

Abstract

Background: COPD exacerbations are responsible for the morbidity and mortality of this disease. The relationship between exacerbations and patient-related clinical outcomes is not clearly understood.

Methods: A retrospective analysis of two 1-year, placebo-controlled clinical trials with tiotropium 18 microg daily was conducted to examine relationships between exacerbations and other clinical outcomes. The relationship between FEV(1), St. George's Respiratory Questionnaire (SGRQ), and the transition dyspnea index (TDI) were examined based on the frequency of exacerbations (0, 1, 2, >2).

Results: 921 patients participated in the trials (mean age 65 years, mean FEV(1) = 1.02 L (39% predicted). The percent change from baseline in FEV(1) in the tiotropium group was +12.6%, +12.0%, +2.1% and +8.9%; and in the placebo group was -3.4%, -3.4%, -5.7% and -6.7% for exacerbation frequencies of 0, 1, 2, >2, respectively. Compared with baseline, the largest improvement in SGRQ occurred in patients with no exacerbations. In the placebo group, there was a significant association between an increased frequency of exacerbations and worsening SGRQ scores. A reduction in exacerbation rates of 4.4% to 42.0% such as that shown in this study cohort was associated with meaningful changes in questionnaire based instruments.

Conclusions: In the placebo-treated patients increased frequency of exacerbations was associated with larger decrements in FEV(1), TDI, and SGRQ. A reduction in the frequency of exacerbations is associated with changes that are considered meaningful in these clinical outcomes.

Keywords: FEV1; chronic obstructive pulmonary disease; dyspnea; exacerbations; quality of life.

References

    1. Global Initiative for Chronic Obstructive Lung Disease. NHLBI/WHO workshop report. Bethesda: National Heart, Lung and Blood Institute; Apr, 2001. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. Update November 2006, GOLD website. Available at: .
    1. Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC. Chronic obstructive pulmonary disease surveillance – United States, 1971–2000. MMWR. 2002;51:1–16.
    1. Murray CGL, Lopez AD. Evidence-based health policy-lessons from the global burden of disease study. Science. 1996;274:740–743.
    1. Friedman M, Witek TJ, Jr, Serby CW, et al. Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared to ipratropium alone and albuterol alone in chronic obstructive pulmonary disease. Chest. 1999;115:635–641.
    1. National Heart, Lung, and Blood Institute. Morbidity and Mortality: 2002 Chart Book on Cardiovascular, Lung, and Blood Diseases. Bethesda, Md: US Department of Health and Human Services, Public Health Service, National Institutes of Health; May, 2002.
    1. Friedman M, Hilleman DE. Economic burden of chronic obstructive pulmonary disease. Pharmacoeconomics. 2001;19:245–254.
    1. Seemungal TAR, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157:1418–1422.
    1. Kanner RE, Anthonisen NR, Connett JE for the Lung Health Study Research Group. Lower respiratory illnesses promote FEV, decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164:358–364.
    1. Plant PK, Owen JL, Elliott MW. Non-invasive ventilation in acute exacerbations of chronic obstructive pulmonary disease: long term survival and predictors of in-hospital outcome. Thorax. 2001;56:708–712.
    1. Connors AF, Dawson NV, Thomas C, et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. Am J Respir Crit Care Med. 1996;154:959–967.
    1. Almagro P, Calbo E, Ochoa de Echaguen A, et al. Mortality after hospitalization for COPD. Chest. 2002;121:1441–1448.
    1. Soler-Cataluna JJ, Martinez-Garcia MA, Roman Sanchez P, et al. Severe acute exacerbations amd mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005;60:925–931.
    1. Miravitlles M, Murio C, Guerrero T, Gisbert R on behalf of the DAFNE study group. Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest. 2002;121:1449–1455.
    1. Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimally clinically important difference. Control Clin Trials. 1989;10:407–415.
    1. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. Am Rev Respir Dis. 1992;145:1321–1327.
    1. Jones PW. Interpreting thresholds for a clinically significant change in health status in asthma and COPD. Eur Resp J. 2002;19:398–404.
    1. Disse B, Speck GA, Rominger KL, Witek TJ, Hammer R. Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease. Life Sci. 1999;64:457–464.
    1. Casaburi R, Mahler DA, Jones PW, Wanner A, San Pedro G, ZuWallack RL, et al. A long-term evaluation of once-daily tiotropium in chronic obstructive pulmonary disease. Eur Respir J. 2002;19:217–224.
    1. Vincken W, van Noord JA, Greefhorst APM, Bantje ThA, Kesten S, Korducki L, et al. Improved health outcomes in patients with COPD during 1 yr’s treatment with tiotropium. Eur Respir J. 2002;19:209–216.
    1. Brusasco V, Hodder R, Miravitlles M, Korducki L, Towse L, Kesten S. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax. 2003;58:399–404.
    1. O’Donnell D, Flüge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J. 2004;23:832–840.
    1. Maltais F, Hamilton A, Marciniuk D, et al. Improvements in symptom-limited exercise performance over eight hours with once-daily tiotropium in patients with COPD. Chest. 2005;128:1168–1178.
    1. Dusser D, Bravo ML Iacono on behalf of the MISTRAL study group. The effect of tiotropium on exacerbations and airflow in patients with COPD. Eur Resp J. 2006;27:547–555.
    1. Niewoehner DE, Rice K, Cote C, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergics bronchodilator. Ann Intern Med. 2005;143:319–326.
    1. Standardization of spirometry – 1994 update: statement of the American Thoracic Society. Am J Respir Crit Care Med. 1995;152:S77–S120.
    1. Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of dyspnea: contents, interobserver agreement and physiologic correlates of two new clinical indexes. Chest. 1984;85:751–758.
    1. Witek TJ, Mahler DA. Meaningful effect size and patterns of response of the transition dyspnea index. J Clin Epidemiol. 2003;56(3):248–255.
    1. Witek TJ, Mahler DA. Minimal important difference of the transition dyspnoea index in a multinational clinical trial. Eur Respir J. 2003;21(2):267–272.
    1. Rodriquez-Roisin R. Towards a consensus definition for COPD exacerbations. Chest. 2000;117:398S–401S.
    1. Celli BR, MacNee W committee members. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Resp J. 2004;23:932–946.
    1. Donaldson GC, Seemungal TAR, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57:847–852.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅